8:00 am Morning Networking Coffee

8:50 am Chair’s Opening Remarks

Expanding the E3 Ligase Repertoire to Unlock Novel Druggable Targets & Broaden the Therapeutic Application of Molecular Glues

9:00 am Leveraging E3 Ligase-Agnostic Discovery to Identify, Optimize and Characterize Novel Cyclin K Molecular Glue Degraders

9:30 am Machine Learning for Rapid Screening of Weak Degrons Across Multiple E3 Ligases

  • Randolph Lopez Co-founder & Chief Technology Officer, A-Alpha Bio Inc.

10:00 am Morning Networking Break & Poster Session

Mechanistic Characterization of Molecular Glues to Unravel the Diversity in Degrading, Activating & Stabilizing Functions

11:00 am Spearheading Stabilization as an Emerging Approach to Expand the Clinically Relevant Target Space of Next-Generation Molecular Glues

  • Yongxin Han Executive Vice President & Head of Drug Discovery, Nested Therapeutics

11:30 am Leveraging AI and Cryo-EM for the Discovery of Proximity-Inducing Molecular Glues

12:00 pm MOPEDTM: A Novel Platform for the Discovery of Molecular Glues

  • Corey Strickland Vice President & Head of Molecular Technology, Proteovant Therapeutics

12:30 pm Networking Lunch Break

Addressing Pharmacological Unknowns & Understanding Regulatory Packages to Drive Pre- Clinical & Clinical Progression

1:30 pm Round Table Discussion: Leveraging the Clinical Learnings from the First Generation of Molecular Glue to Accelerate the Progression of Safe & Effective Novel Candidates

2:30 pm The Pin Platform for Discovering & Developing Molecular Glues for New E3 Ligases

  • Byron DeLaBarre Chief Technology Officer & Head of Platform, Pin Therapeutics

3:00 pm Leveraging the Progression of Molecular Glues in the Clinic to Better Inform the Translation of Novel Glue Candidates

3:30 pm Chairs Closing Remarks & End of 2nd Molecular Glue Drug Development Summit 2024